Valuation: Actavis Inc

Market Cap 63.66B 57.98B 53.43B 48.6B 91.17B 5,895B 95.82B 650B 258B 3,220B 239B 234B 10,105B P/E 2018
-8.76x
P/E 2019 -11.9x
Enterprise Value 80.96B 73.74B 67.95B 61.81B 116B 7,497B 122B 827B 329B 4,095B 304B 297B 12,852B EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
09/11 Allergan Aesthetics Announces Results from HARMONY IN DIVERSITY and HALO Phase 4 Studies of Aesthetic Treatment in Adults on GLP-1 Medications CI
04/11 Allergan Aesthetics To Present New Research On Aesthetic Care Following Medical Weight Loss And Evolving Patient Needs At ASDS 2026 CI
22/10 Allergan Aesthetics presents its latest scientific advances Zonebourse
29/09 Abbvie Through Allergan Aesthetics Receives Health Canada Authorization for Boey for Frown Lines CI
18/09 Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications CI
15/09 Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies CI
02/09 Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist CI
08/04 Allergan Aesthetics Opens New Ami Training Center in Austin CI
01/04 Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting CI
30/03 Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting CI
19/03 Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions CI
05/03 Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients CI
13/11 Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence CI
Manager TitleAgeSince
Director of Finance/CFO 56 01/12/2016
Director TitleAgeSince
Director/Board Member - 08/05/2020
Director/Board Member - 08/05/2020
Director/Board Member - 08/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.33%-4.76%+25.01%+75.64% 452B
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2018 2019
Net sales 15.79B 14.38B 13.25B 12.05B 22.61B 1,462B 23.76B 161B 64.09B 798B 59.23B 57.99B 2,506B 16.09B 14.65B 13.5B 12.28B 23.04B 1,490B 24.22B 164B 65.32B 814B 60.37B 59.09B 2,554B
Net income -5.1B -4.64B -4.28B -3.89B -7.3B -472B -7.67B -52.06B -20.69B -258B -19.12B -18.72B -809B -5.27B -4.8B -4.42B -4.02B -7.55B -488B -7.93B -53.84B -21.4B -267B -19.78B -19.36B -837B
Net Debt 21.89B 19.94B 18.37B 16.71B 31.35B 2,027B 32.95B 224B 88.87B 1,107B 82.13B 80.4B 3,475B 17.3B 15.76B 14.52B 13.21B 24.78B 1,602B 26.05B 177B 70.25B 875B 64.93B 63.56B 2,747B
Logo Actavis Inc
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
-